Predictors and Outcomes in Patients With Sickle Cell Disease
Public ClinicalTrials.gov record NCT03431935. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Longitudinal Examination of Predictors and Outcomes of Sickle Cell Disease Healthcare Transition
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Children with sickle cell disease (SCD) are living longer with the advent of medical advances such as prophylactic penicillin, chronic transfusion, and hydroxyurea. Despite greater longevity in SCD, the period following the transition from pediatric to adult care is critical; youth aged 18-30 years are at high risk for mortality and have high rates of healthcare utilization, leading to high healthcare costs. As such, health care transition (HCT) programs have been created to prepare patients for adult-centered care and subsequently, improve health outcomes. However, very few programs have been evaluated for effectiveness in achieving optimal health outcomes in SCD. This paucity of program evaluation is attributed to a lack of identifiable predictors and outcomes. Researchers at St. Jude Children's Research Hospital want to identify factors and patterns of successful HCT. This information will be used to develop approaches to best evaluate HCT interventions and identify areas of improvement of HCT programming. PRIMARY OBJECTIVE: Describe hospital utilization, treatment adherence, and health-related quality of life in a cohort of patients with sickle cell disease (SCD) who will transfer to adult care during the study period. SECONDARY OBJECTIVE: Examine the associations between various factors and health care transition (HCT) outcomes.
Study identification
- NCT ID
- NCT03431935
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 94 participants
Conditions and interventions
Conditions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 16 Years to 20 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 30, 2018
- Primary completion
- Jan 30, 2022
- Completion
- May 25, 2023
- Last update posted
- Feb 5, 2026
2018 – 2023
United States locations
- U.S. sites
- 2
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Methodist Adult Comprehensive Sickle Cell Center | Memphis | Tennessee | 38104 | — |
| St. Jude Children's Research Hospital | Memphis | Tennessee | 38105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Sickle Cell Disease trials
Other public records listing Sickle Cell Disease. Sorted by last update posted; newest first. Not a recommendation.
- NCT07776444: Cerebrovascular Reactivity Measurements With High-Density Diffuse Optical Tomography Recruiting
- NCT07656415: A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD) Recruiting
- NCT02447874: Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease Recruiting
- NCT07616154: Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease Recruiting
- NCT07708350: Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Sickle Cell Disease Not yet recruiting
- NCT01499888: Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD) Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03431935, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 5, 2026 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03431935 live on ClinicalTrials.gov.